Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma
McGregor BA, Lalani AA, Xie W, Steinharter JA, Bakouny Z, Martini DJ, Fleischer JH, Abou-Alaiwi S, Nassar A, Nuzzo PV, Kaymakcalan MD, Braun DA, Wei XX, Harshman LC, Bilen MA, Choueiri TK. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. European Journal Of Cancer 2020, 135: 203-210. PMID: 32599410, DOI: 10.1016/j.ejca.2020.05.009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngiogenesis InhibitorsAnilidesAntineoplastic Combined Chemotherapy ProtocolsBostonCarcinoma, Renal CellFemaleGeorgiaHumansImmune Checkpoint InhibitorsKidney NeoplasmsMaleMiddle AgedProtein Kinase InhibitorsPyridinesRetrospective StudiesTime FactorsTreatment OutcomeConceptsMetastatic clear cell renal cell carcinomaImmune checkpoint blockadeClear cell renal cell carcinomaActivity of cabozantinibRenal cell carcinomaOverall survivalTreatment failureCheckpoint blockadeCell carcinomaDose reductionAnti-PD-1/PD-L1International Metastatic RCC Database ConsortiumVascular endothelial growth factor inhibitorsSubsequent-line treatmentUse of cabozantinibIntermediate-risk groupMedian overall survivalMedian TTFHalf of patientsNew safety signalsPalmar-plantar erythrodysesthesiaPrimary progressive diseaseGrowth factor inhibitorsOverall response rateMost common reasons